

Fig. E-1A

Illustration demonstrating the sources searched to identify eligible studies.

FIGURE E1-B: SEARCH FLOW OF SEPARATE ELECTRONIC DATABASES

Legend: This figure demonstrates the detailed flow of different electronic databases searched.




Illustration demonstrating the detailed flow of the different electronic databases that were searched.

Bajammal eAppendix

01 1	0.1.1		PD (marked)	
Study or sub-category	Calcium phosphate n/N	Control n/N	RR (random) 95% Cl	RR (random) 95% Cl
or sub-category	n/n	n/in	95% Ci	95% CI
01 Calcium phosphate ve	ersus no substitute			
Cassidy 2003	4/161	10/162		0.40 [0.13, 1.26]
Sanchez-Sotelo 2000	7/55	15/55		0.47 [0.21, 1.05]
Subtotal (95% CI)	216	217		0.44 [0.23, 0.86]
Total events: 11 (Calciun	phosphate), 25 (Control)			
Test for heterogeneity: C	hi ² = 0.04, df = 1 (P = 0.84), P = 0%			
Test for overall effect: Z	= 2.40 (P = 0.02)			
02 Calcium phosphate ve	ersus autogenous bone graft			
Dickson 2002	4/9	6/13	_	0.96 [0.38, 2.46]
Subtotal (95% CI)	9	13		0.96 [0.38, 2.46]
Total events: 4 (Calcium	phosphate), 6 (Control)			
Test for heterogeneity: n	ot applicable			
Test for overall effect: Z	= 0.08 (P = 0.94)			
Total (95% CI)	225	230		0.57 [0.33, 0.99]
Total events: 15 (Calciun	phosphate), 31 (Control)			
Test for heterogeneity: C	hi ² = 1.89, df = 2 (P = 0.39), F = 0%			

Fig. E-2A

Figs. E-2A and E-2B Meta-analysis (Forest) plots of outcomes. **Fig. E-2A** Relative risk of the presence of pain depending on the control group (autogenous bone graft or no substitute) in the trials.

Study				
State of the state	Calcium phosphate	Control	RR (random)	RR (random)
or sub-category	n/N	n/N	95% Cl	95% Cl
01 Calcium phos	phate versus no substitute			
Cassidy 2003	4/161	10/162		0.40 [0.13, 1.26]
Sanchez-Soteld	2000 7/55	15/55		0.47 [0.21, 1.05]
Subtotal (95% C	216	217		0.44 [0.23, 0.86]
Total events: 11	(Calcium phosphate), 25 (Control)			
Test for heterog	eneity: Chi ² = 0.04, df = 1 (P = 0.84), P = 0%			
	ffect: Z = 2.40 (P = 0.02)			
02 Calcium phos	phate versus autogenous bone graft			
Dickson 2002	4/9	6/13		0.96 [0.38, 2.46]
Subtotal (95% C	9	13		0.96 [0.38, 2.46]
Total events: 4 (Calcium phosphate), 6 (Control)			
Test for heterog	eneity: not applicable			
Test for overall	ffect: Z = 0.08 (P = 0.94)			
Total (95% Cl)	225	230		0.57 [0.33, 0.99]
	(Only and the set of a log and the log		-	
	(Calcium phosphate), 31 (Control)			
Total events: 15	(Calcium phosphate), 31 (Control) eneity: Chi ² = 1.89, df = 2 (P = 0.39), P = 0%			

Fig. E-2B

Relative risk of the presence of pain depending on the type of fracture (radial fracture or multiple fractures) in the trials.

Bajammal eAppendix

Study	Calcium phosphate	Control	RR (random)	RR (random)
or sub-category	n/N	n/N	95% Cl	95% CI
01 Calcium phosphate versus	no substitute	N		
Cassidy 2003	46/161	40/162		1.16 [0.80, 1.66]
Sanchez-Sotelo 2000	10/55	23/55		0.43 [0.23, 0.83]
Subtotal (95% CI)	216	217		0.74 [0.28, 1.92]
Total events: 56 (Calcium phos	sphate), 63 (Control)			
Test for heterogeneity: Chi2 =	6.79, df = 1 (P = 0.009), P = 85.3	3%		
Test for overall effect: Z = 0.6	3 (P = 0.53)			
02 Calcium phosphate versus	autogenous bone graft			
Dickson 2002	1/9	3/11 🔶	-	0.41 [0.05, 3.28]
Larsson 2004	1/13	2/13 🔶		0.50 [0.05, 4.86]
Russell 2004	6/82	10/38 -		0.28 [0.11, 0.71]
Subtotal (95% CI)	104	62		0.32 [0.14, 0.70]
Total events: 8 (Calcium phosp	ohate), 15 (Control)			
Test for heterogeneity: Chi ² =	0.29, df = 2 (P = 0.87), F = 0%			
Test for overall effect: Z = 2.8	2 (P = 0.005)			
Total (95% Cl)	320	279		0.54 [0.26, 1.13]
Total events: 64 (Calcium phos	sphate), 78 (Control)			
Test for heterogeneity: Chi ² =	12.95, df = 4 (P = 0.01), F = 69.1	1%		
Test for overall effect: Z = 1.6	4 (P=0.10)			

Fig. E-3A

Figs. E-3A and E-3B Meta-analysis (Forest) plots of outcomes. **Fig. E-3A** Relative risk of loss of reduction depending on the control group (autogenous bone graft or no substitute) in the trials.




Fig. E-3B

Relative risk of loss of reduction depending on the type of fracture (radial fracture or multiple fractures) in the trials.